Familial hypercholesterolemia: etiology, diagnosis and new treatment options

Area of Science:

• Cardiovascular Medicine
• Genetics
• Pharmacology

Background:

• Familial hypercholesterolemia (FH) is a prevalent genetic disorder characterized by significantly elevated low-density lipoprotein cholesterol (LDL-C).
• FH leads to premature cardiovascular disease, with both heterozygous and homozygous forms existing.
• Despite effective LDL-C lowering strategies preventing morbidity and mortality, FH remains significantly underdiagnosed.

Purpose of the Study:

• To review the evidence for newer lipid-lowering drugs in treating Familial hypercholesterolemia (FH).
• To focus on the efficacy and safety of these novel therapeutic agents in FH patients.
• To address the unmet need for effective treatments when guideline-recommended LDL-C targets are not achieved.

Main Methods:

• Review of available evidence on newer lipid-lowering drug classes in FH patients.
• Analysis of efficacy and safety data for specific drug classes: apolipoprotein-B synthesis inhibitors, microsomal transfer protein inhibitors, cholesterol ester transfer protein inhibitors, and PCSK9 inhibitors.
• Discussion of current therapeutic mainstays (statins, apheresis) and their limitations in achieving target LDL-C levels.

Main Results:

• Four classes of newer drugs (apolipoprotein-B synthesis inhibitors, microsomal transfer protein inhibitors, CETP inhibitors, PCSK9 inhibitors) offer potential advances in FH management.
• These agents, including mipomersen, lomitapide, anacetrapib, evacetrapib, evolocumab, and alirocumab, are discussed regarding their effectiveness in lowering LDL-C.
• The review focuses on the safety profiles of these novel FH treatments.

Conclusions:

• Newer lipid-lowering drug classes represent promising therapeutic options for patients with Familial hypercholesterolemia.
• These agents can help achieve target LDL-C levels in FH patients, particularly when conventional therapies are insufficient.
• Further evaluation of efficacy and safety is crucial for integrating these drugs into FH treatment guidelines.